checkedPsychopharmacology and Psychiatry Updates2026-11-02last verified 2026-11-03

are there 10 placebo-controlled trials of prazosin for sleep and other problems in ptsd?

verdict: confirmed
the primary source says it, at that magnitude
“We now have 10 placebo-controlled trials that are in the literature of Prazoson for sleep and other problems in PTSD.”

a guest, Dr. David Osser, psychiatrist treating PTSD in the VA system said on Psychopharmacology and Psychiatry Updates, 2026-11-02, at 03:47. hear it in context →

the episode: Prazosin for PTSD Nightmares (at 03:47). we link the show's own page; we do not re-host audio.

first, the part that holds

the count holds up. two separate systematic reviews, published in 2023 and 2025, each found exactly 10 randomized placebo-controlled trials of prazosin in people with PTSD. the trials measured nightmares, insomnia, overall PTSD symptoms and, in some, alcohol use.

what we found when we went and looked

we checked the number against two recent systematic reviews. a 2025 meta-regression in Progress in Neuro-Psychopharmacology & Biological Psychiatry searched five databases in November 2023 and included 10 placebo-controlled randomized trials with 648 patients. a separate 2023 meta-analysis of drug trials for nightmares also counted 10 placebo-controlled prazosin trials. at least one more published placebo-controlled trial exists: a 2012 three-arm study in 50 military veterans with sleep complaints. it falls outside the 2025 review's rules, so depending on how you draw the line, "10" is accurate or slightly low. the number of trials says nothing about how they came out, though. the largest one, 304 veterans, found no difference from placebo, and across all 10 the pooled results show a benefit for nightmares and insomnia but not a statistically significant one for overall PTSD symptoms.

assertion by assertion

assertionverdictwhat the record says
there are 10 published placebo-controlled trials of prazosin in PTSDconfirmedthe 2025 systematic review included 10 placebo-controlled RCTs (648 patients) published 2003-2023. a 2023 meta-analysis of drug treatments for nightmares independently counted 10 placebo-controlled prazosin trials. the exact count depends on inclusion rules: a 2012 placebo-controlled three-arm trial in veterans with sleep complaints is published but was not in the 2025 set [1][2][3]
the trials address sleep and other problems in PTSDconfirmedthe 10 trials' outcomes include nightmares, insomnia or sleep quality, total PTSD symptom severity, and in two trials of veterans with alcohol use disorder, drinking outcomes [1][2]
popular framing: 10 placebo-controlled trials means prazosin is proven to work for PTSDoverstatedpooled across the 10 trials: nightmares SMD -0.641 (p=0.025), insomnia SMD -0.654 (p=0.043), overall PTSD SMD -0.428 (p=0.077, not significant). heterogeneity was very high (I2 83-89%). four of the trials, including the largest (n=304 veterans), found no benefit or favored placebo. two trials enrolled 8 and 10 people [1][2]

both directions

for the speaker: two independent reviews come up with the same number, 10. both include trials in civilians, active-duty soldiers and veterans, and both pool them to find a moderate benefit for trauma-related nightmares: SMD about -0.64 in the 2025 review and g = 0.54 in the 2023 review. at least one more published placebo-controlled trial (2012, 50 veterans) sits outside the 2025 set, so 10 is, if anything, a floor.

against: the count tells you how much research exists, not what it found. most of the 10 trials are small, and two enrolled 8 and 10 people. the one large trial, 304 veterans in a 2018 VA cooperative study, found no difference from placebo on nightmares, sleep or PTSD symptoms, and the 2025 review says that trial led to evidence ratings being downgraded. pooled, the effect on overall PTSD symptoms is not statistically significant, and heterogeneity between trials is very high (I2 above 80%). so the trials point different ways.

what this cannot say

the speaker did not name a source, so we can't tell which set of trials they had in mind. any trial count depends on the inclusion rules: whether to count trials with active comparators, trials where not everyone had a formal PTSD diagnosis, pilot studies, or crossover designs. the 2025 review searched only up to November 2023 and excluded gray literature, so trials published since then would not be in its count. we read abstracts and review summaries, not every trial report, and we did not run our own database search.

sources, each one fetched and read

  1. Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2025. doi:10.1016/j.pnpbp.2025.111253 What we read there: 10 placebo-controlled RCTs, 648 patients; prazosin improved insomnia (SMD = -0.654, p = 0.043) and nightmares (SMD = -0.641, p = 0.025), but not overall PTSD symptoms (SMD = -0.428, p = 0.077); I2 82.8-89.2%; the PACT trial demonstrated no improvement in nightmares or PTSD symptoms Fetched 2026-11-03 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC12985405/
  2. The effects of pharmacological treatment of nightmares: a systematic literature review and meta-analysis of placebo-controlled, randomized clinical trials. International Journal of Environmental Research and Public Health, 2023 What we read there: 10 placebo-controlled RCTs of prazosin, mostly in veterans or soldiers with PTSD; pooled effect on nightmares g = 0.54 (95% CI 0.10-0.99), with considerable variation between studies Fetched 2026-11-03 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC9820008/
  3. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. Journal of Psychosomatic Research, 2012;72(2):89-96. doi:10.1016/j.jpsychores.2011.11.010 What we read there: 50 veterans with sleep complaints comorbid with stress-related disorder symptoms including PTSD randomized to prazosin, behavioral sleep intervention, or placebo for eight weeks; a published placebo-controlled trial outside the 2025 review's 10 Fetched 2026-11-03 (HTTP 200). https://pubmed.ncbi.nlm.nih.gov/22281448/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam